Yissum Ltd. and Eucalyptus Sign Licensing Agreement for the Development of a Small Molecule for the Treatment of Neurodegenerative Diseases
1/8/2008 8:54:14 AM
JERUSALEM--(BUSINESS WIRE)--Yissum Ltd., the technology transfer company of the Hebrew University of Jerusalem, today announced that it has licensed an orally–available small molecule for several biological indications including the treatment of neurodegenerative diseases to Eucalyptus Ltd. The molecule is an antioxidant that overcomes the blood-brain barrier.
comments powered by